Inhalers to treat asthma and COPD

PublicationNr. 3 - 30 maart 2017
Year51
SectionArticle
Pages25-33

Various inhalation  products and inhalers are currently on the market, and their characteristics may differ between types of product (dry powder, aerosol, nebuliser) but also between types of inhalers. Inhalers are subject to drug registration regulations as they are provided together with the medication. In addition, they are subject to a number of supplementary guidelines regarding the quality of the inhalers and the bio-equivalence of new inhalers. What type of inhaler will be suitable for a particular patient theoretically depends on the type of drug that is to be delivered, the particle size of the inhaled drug, the speed of inhalation, the patient’s respiratory power and volume and the patient’s ability to use the correct inhalation technique. The characteristics of the inhaler may affect the distribution of the drug over the lungs, but research has found no clear differences in efficacy between the various types of inhalers, although there are indications of a potential problem of cardiovascular adverse effects of tiotropium in the Respimat inhaler.

The choice of a particular type of inhaler should therefore be based on other criteria, such as side-effects, ease of use and costs. In practice, care providers often have to rely on their own experience, which implies that prescription practices are unfortunately not evidence-based. The large number of different inhalers available makes it impossible for care providers to gain enough experience with all types. Hence, it is advisable for them to gain experience with a limited range of inhalers. If the efficacy of a particular inhaler proves to be insufficient, the first thing to try is to improve the patient’s inhalation technique, rather than switching to another inhaler. It is often claimed that aerosols (pressurised metered dose inhalers, or pMDIs) require good coordination between hand and lungs and are therefore more difficult to use correctly. However, there is insufficient evidence to state a preference based on this criterion. In addition, patients are advised to use the pMDI in combination with a spacer, which invalidates this argument. Some drugs and fixed combinations are only available with one particular inhaler, making it difficult to prescribe only one type of inhaler to each patient. The preference for nebulisers to treat exacerbations expressed in the guidelines of the Dutch College of General Practitioners cannot be substantiated with objective evidence. Hence, the choice of a pMDI with a spacer and possibly a facemask or nebuliser could be determined by cost considerations.

Reports to the Dutch adverse effects reporting centre Lareb concerning an increase in the number of reported adverse effects of the Sandoz salbutamol inhaler appear to be due to a change in the product, rather than to a defective or  inferior product, although it remains to be seen if the peak in reports will decline as patients have had more time to get used to the new inhaler. The same goes for reports about the Vincion fluticason/salmeterol inhaler by Focus Pharma. Both reports do, however, show that switching inhalers purely based on the health insurers’ preference policy involves adjusting inhalation instructions and causes discomfort and anxiety among patients, and should therefore be avoided.

Manufacturers frequently advertise the advantages of their inhalers. Their claims are, however, insufficiently substantiated by research. As long as sound scientific research is lacking, the initial choice of a particular inhaler can be made on the basis of prices and patient preferences.

References*

  1. Smeele I, Barnhoorn MJM, Broekhuizen BDL, Chavannes NH, In ’t Veen JCCM, Van der Molen T, et al. NHG-Standaard Astma bij volwassenen (derde herziening). Huisarts Wet 2015; 58: 142-154.
  2. Snoeck-Stroband JB, Schermer TRJ, Van Schayck CP, Muris JW, Van der Molen T, Veen JCCM In ’t, et al. NHG-Standaard COPD (derde herziening). Huisarts Wet 2015; 58:198-211.
  3. Feiten en cijfers over volksgezondheid en zorg. RIVM 2017. Via: https://www.volksgezondheidenzorg.info.
  4. Bindels PJE, Van der Griendt EJ, Grol MH, Van Hensbergen W, Steenkamer TA, Uijen JHJM, et al. NHG-Standaard Astma bij kinderen (Derde herziening). Huisarts Wet 2014; 57: 70-80.
  5. Cijfers GIP-databank December 2016. Via: www.gipdatabank.nl.
  6. Zwikker HE, Vervloet M, Koster E, Philbert D, Damen N, van Dijk L. Gevolgen van preferentiebeleid en farmaceutische zorginkoop. Nivel, Utrecht 2015.
  7. De Boer A, Ruijgrok L. Luchtwegen. In: Recepteerkunde. Bouwman-Boer Y. Houten: Bohn Stafleu van Loghum, , 2009.
  8. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1: 67-86.
  9. Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev 2013; 14: 112-118.
  10. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1331.
  11. De Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Can ’extrafine’ dry powder aerosols improve lung deposition? Eur J Pharm Biopharm 2015; 96: 143-151.
  12. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005; 172: 1497-1504.
  13. Hagedoorn P, Klemmeier T. Inhalatie  technologie&instructie 2ed. Beuningen: Esculaap Media, 2015.
  14. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377: 1032-1045.
  15. Goed gebruik van inhalatiemiddelen. Amersfoort: Longalliantie Nederland, 2014.
  16. FDA. Jurisdictional Update: Metered Dose Inhalers, Spacers and Other Accessories. Via: http://www.fda.gov/combinationproducts/jurisdictionalinformation/jurisdictionalupdates/ucm103179.htm.
  17. European Medicines Agency. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Via: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A01993L0042-20071011.
  18. European Medicines Agency. Pharmaceutical quality of inhalation and nasal products. Via: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000805.jsp&mid=WC0b01ac0580028eb3.
  19. European Medicines Agency. Guideline on the requirements for clinical documentation for Orally Inhaled Products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and for use in the treatment of Asthma in children and adolescents. Via: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500003504&mid=WC0b01ac058009a3dc.
  20. European Medicines Agency . Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). Via: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500003557&mid=WC0b01ac058009a3dc.
  21. European Medicines Agency. Guideline for PMS studies for metered dose inhalers with new propellants. Via: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500003552&mid=WC0b01ac058009a3dc.
  22. FDA. Guidance for Industry – Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Via: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070573.pdf.
  23. FDA. Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators. Via: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm081282.htm.
  24. Ram FS, Brocklebank DD, White J, Wright JJ, Jones P. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. Cochrane Database Syst Rev 2002: CD002158.
  25. Ram FS, Brocklebank DD, Muers M, Wright JJ, Jones P. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.
    Cochrane Database Syst Rev 2002: CD002170.
  26. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013: CD000052.
  27. Geffen WH van, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev 2016: CD011826.
  28. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007; 61: 1874-1883.
  29. Ram FS, Carvallho CR, White J. Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis 2011; 6: 129-139.
  30. Virchow JC, Rodriguez-Roisin R, Papi A, Shah TP, Gopalan G. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma. BMC Pulm Med 2016; 16: 42.
  31. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938.
  32. Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J 2017; 49: pii:1601794.
  33. Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, Lavorini F, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2016; 12 :59-71.
  34. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491-1501.
  35. Loke YK, Singh S, Furberg CD. Tiotropium and the risk of death in COPD [correspondence]. N Engl J Med 2014; 370: 480-481.
  36. Trotta F, Spila-Alegiani S, Da Cas R, Rajevic M, Conti V, Venegoni M, et al. Cardiovasuclar safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study. PloS One 2017; 12: e176276.
  37. FDA. Enforcement Reports. Via: http://www.accessdata.fda.gov/scripts/ires/index.cfm#tabNav_advancedSearch.
  38. Bijwerkingencentrum Lareb. Decreased effectivity associated with the revised formulation of the salbutamol aerosol from Sandoz®. 2015. Via: http://databankws.lareb.nl/Downloads/Signals_2015_Salbutamol_efficacy_lack.pdf.
  39. Productinformatie salbutamol Sandoz aerosol rvg 27018 = 26833. Via: www.geneesmiddeleninformatiebank.nl.
  40. Productinformatie salbutamol Sandoz aerosol rvg 34424. Via: www.geneesmiddeleninformatiebank.nl.
  41. College ter Beoordeling van Geneesmiddelen. Publiek beoordelingsrapport Salbutamol Sandoz aërosol 100 microgram/dosis (RVG 34424) – Rapport – College ter Beoordeling van Geneesmiddelen 2016. Via: https://www.cbg-meb.nl/documenten/rapporten/2016/09/23/par-salbutamol-rvg-34424.
  42. Bijwerkingencentrum Lareb. Salmeterol with fluticasone and lack of efficacy after drug substitution 2016. Via: www.lareb.nl.
  43. CBG Nieuwsbericht. Begeleid patiënten bij omzetting van salmeterol/fluticason inhalatiemiddelen. Maart 2017. Via: https://www.cbg-meb.nl/actueel/nieuws/2017/03/20/begeleid-patienten-bij-omzetting-van-salmeterol-fluticason-inhalatiemiddelen.

*The literature refers to the Dutch text